Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Cough in Idiopathic pulmonary fibrosis (IPF) - Market Insights, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
This report focuses on the global Idiopathic Pulmonary Fibrosis (IPF) market and its expanding trajectory regarding the specific symptom of cough. The report presents an all-encompassing view of the IPF market dynamics, including the diagnosis, severity of symptoms, current therapeutic strategies, and future growth prospects.
Highlighting the significant impact of cough in IPF on patients' quality of life, the report brings to attention the projected growth of this niche sector in seven major markets (7MM)—the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. According to the research, the market for Cough in IPF is forecasted to experience consistent growth through 2034, fueled by an anticipated rise in diagnosed prevalent cases and the introduction of emerging therapies that could transform current treatment paradigms.
Current treatment approaches largely consist of off-label therapies, with corticosteroids and neuromodulators being the mainstay. However, a pressing need for effective, specifically targeted treatments persists. Emerging drugs like Orvepitant Maleate and Haduvio (nalbuphine ER) hold substantial promise, and their potential market approval could lead to a significant shift towards more efficacious management of cough-related symptoms in IPF patients.
The comprehensive report dissects each segment of the market based on in-depth insights into epidemiology data, current and potentially game-changing drug profilers, and a detailed forecast spanning from 2020 to 2034. It chronicles the complexities of diagnosing and managing this chronic condition, exploring the multifactorial nature of cough in IPF patients, alongside the pipeline development activities spearheaded by key pharmaceutical players.
The research makes note of the critical need for advanced therapeutic options to improve patient outcomes, particularly considering the symptom's association with heightened morbidity. The study employs robust analytical frameworks, including SWOT and Conjoint Analysis, to generate a nuanced picture of market risks, opportunities, and the competitive landscape.
In-depth interviews with industry experts and key opinion leaders supplement the findings, bringing real-world experiences and expectations into the discussion. These insights illuminate the report by addressing a spectrum of crucial factors, from treatment accessibility and reimbursement landscapes to patient adherence challenges and unmet clinical needs.
A selection of companies mentioned in this report includes:
- NeRRe Therapeutics
- Trevi Therapeutics
- Algernon Pharmaceuticals/Seyltx Inc.
- Melius Pharma AB
- Cellular Sciences/Emphycorp
For more information about this report visit https://www.researchandmarkets.com/r/inbxbn
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
